FLC
MURA

Fifth Lane Capital’s Mural Oncology MURA Stock Holding History

Fifth Lane Capital’s Portfolio MURA Stock Details MURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,001
Closed -$24.7K – 113
2025
Q2 		$24.7K Buy
+10,001
New +$23.6K 0.03% 64
2024
Q2 		– Sell
-45,000
Closed -$220K – 153
2024
Q1 		$220K Buy
+45,000
New +$218K 0.19% 72

Other funds holding MURA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Fifth Lane Capital's MURA Position: Q3 2025 in Review

Fifth Lane Capital sold out of Mural Oncology (MURA) in Q3 2025, closing a stake of 10,001 shares — an estimated $24.7K sold.

Fifth Lane Capital first reported a position in MURA in Q1 2024 and held it in 2 quarters. The position peaked at $220K in Q1 2024. 61 funds tracked by Wall St. Rank hold MURA as of Q3 2025.

  • Fifth Lane Capital reported no remaining Mural Oncology position as of Q3 2025 after selling out during the quarter.
  • Fifth Lane Capital sold 10,001 Mural Oncology shares in Q3 2025, an estimated $24.7K.
  • Fifth Lane Capital first reported a position in Mural Oncology in Q1 2024 and held it in 2 quarters.
  • Fifth Lane Capital's Mural Oncology position peaked at $220K in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Mural Oncology as of Q3 2025.

Based on Fifth Lane Capital's 13F filing for Q3 2025, filed 12 Nov 2025.